207 related articles for article (PubMed ID: 25307971)
1. Prognostic relevance of the flow cytometric count of medullar blasts in myelodysplastic syndromes.
Molteni A; Riva M; Cesana C; Speziale V; Nichelatti M; Scarpati B; Greco R; Ravano E; Cairoli R; Rossini S; Morra E
Eur J Haematol; 2015 Jun; 94(6):519-25. PubMed ID: 25307971
[TBL] [Abstract][Full Text] [Related]
2. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of immunophenotypic features of blasts in patients with myelodysplastic syndrome by flow cytometry and its diagnostic significance].
Sun JF; Yang B; Zhang L; Huang Y; Yang J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):632-5. PubMed ID: 22739171
[TBL] [Abstract][Full Text] [Related]
4. Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes.
Sandes AF; Kerbauy DM; Matarraz S; Chauffaille Mde L; López A; Orfao A; Yamamoto M
Cytometry B Clin Cytom; 2013 May; 84(3):157-66. PubMed ID: 23475532
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia.
Wang H; Wang XQ; Xu XP; Lin GW
Eur J Haematol; 2009 Dec; 83(6):550-8. PubMed ID: 19737310
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic application and clinical significance of FCM progress scoring system based on immunophenotyping in CD34+ blasts in myelodysplastic syndromes.
Xu F; Guo J; Wu LY; He Q; Zhang Z; Chang CK; Li X
Cytometry B Clin Cytom; 2013; 84(4):267-78. PubMed ID: 23554290
[TBL] [Abstract][Full Text] [Related]
7. Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells.
Ogata K; Sei K; Saft L; Kawahara N; Porta MGD; Chapuis N; Yamamoto Y
Leuk Res; 2018 Aug; 71():75-81. PubMed ID: 30025279
[TBL] [Abstract][Full Text] [Related]
8. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
[TBL] [Abstract][Full Text] [Related]
9. Value of Quantitative assessment of Myeloid Nuclear Differentiation Antigen expression and other flow cytometric parameters in the diagnosis of Myelodysplastic syndrome.
Somasundaram V; Soni S; Chopra A; Rai S; Mahapatra M; Kumar R; Pati H
Int J Lab Hematol; 2016 Apr; 38(2):141-50. PubMed ID: 26822549
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometry in myelodysplastic syndrome: analysis of diagnostic utility using maturation pattern-based and quantitative approaches.
Chopra A; Pati H; Mahapatra M; Mishra P; Seth T; Kumar S; Singh S; Pandey S; Kumar R
Ann Hematol; 2012 Sep; 91(9):1351-62. PubMed ID: 22526362
[TBL] [Abstract][Full Text] [Related]
11. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
[TBL] [Abstract][Full Text] [Related]
12. Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts.
Font P; Loscertales J; Soto C; Ricard P; Novas CM; Martín-Clavero E; López-Rubio M; Garcia-Alonso L; Callejas M; Bermejo A; Benavente C; Ballesteros M; Cedena T; Calbacho M; Urbina R; Villarrubia J; Gil S; Bellón JM; Diez-Martin JL; Villegas A
Ann Hematol; 2015 Apr; 94(4):565-73. PubMed ID: 25387664
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
[TBL] [Abstract][Full Text] [Related]
14. The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system.
Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
Leukemia; 2016 Mar; 30(3):658-65. PubMed ID: 26503643
[TBL] [Abstract][Full Text] [Related]
15. Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes.
Falco P; Levis A; Stacchini A; Ciriello MM; Geuna M; Notari P; Omedè P; Pautasso M; Prato G; Strola G; Gioia D; Bonferroni M; Cametti G; Ferrero D; Freilone R; Gaidano G; Marinone C; Marmont F; Pollio B; Salvi F; Saglio G; Girotto M;
Eur J Haematol; 2011 Nov; 87(5):409-18. PubMed ID: 21711395
[TBL] [Abstract][Full Text] [Related]
16. [Four-color flow cytometric immunophenotypic features of blasts in myelodysplastic syndromes].
Wu YJ; Li JY; Qiu HR; Xiao B; Zhang JF; Song JH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb; 14(1):50-3. PubMed ID: 16584591
[TBL] [Abstract][Full Text] [Related]
17. [Diagnostic significance of immunophenotyping of bone marrow cells in myelodysplastic syndrome without an increase of marrow blasts].
Xu J; Zhang W; Liu Y; Wan SG; Sun XJ; Zhao H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1477-81. PubMed ID: 20030930
[TBL] [Abstract][Full Text] [Related]
18. Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses.
Loken MR; Chu SC; Fritschle W; Kalnoski M; Wells DA
Cytometry B Clin Cytom; 2009 Jan; 76(1):27-36. PubMed ID: 18548614
[TBL] [Abstract][Full Text] [Related]
19. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes.
Verburgh E; Achten R; Maes B; Hagemeijer A; Boogaerts M; De Wolf-Peeters C; Verhoef G
J Clin Oncol; 2003 Jan; 21(2):273-82. PubMed ID: 12525519
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotypic features of granulocytes, monocytes, and blasts in myelodysplastic syndromes.
Moon HW; Huh JW; Lee M; Hong KS; Chung WS
Korean J Lab Med; 2010 Apr; 30(2):97-104. PubMed ID: 20445324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
